Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Saroglitazar30 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00475 | 35068786 | J Clin Exp Hepatol | Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study. | 2021 | Details |
| A01308 | 34794234 | Biomed Pharmacother | Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids. | 2021 | Details |
| A01843 | 34593018 | BMC Pharmacol Toxicol | Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis. | 2021 | Details |
| A01853 | 34588764 | Drug Des Devel Ther | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | 2021 | Details |
| A02181 | 34471049 | Biol Pharm Bull | Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist. | 2021 | Details |
| A03942 | 33811367 | Hepatology | Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. | 2021 | Details |
| A04466 | 33604254 | J Clin Transl Hepatol | Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. | 2020 | Details |
| A05390 | 33273703 | Sci Rep | Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. | 2020 | Details |
| A05696 | 33152542 | Clin Gastroenterol Hepatol | A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis. | 2020 | Details |
| A06680 | 32782883 | Cureus | An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A07125 | 32613381 | Cell Biol Toxicol | Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. | 2020 | Details |
| A07385 | 32518275 | Sci Rep | The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08014 | 32280349 | Case Rep Med | Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience. | 2020 | Details |
| A09046 | 31889755 | J Clin Exp Hepatol | Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09096 | 31877771 | Cells | Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. | 2019 | Details |
| A09774 | 31614690 | Int J Mol Sci | Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. | 2019 | Details |
| A10755 | 31208414 | Cardiovasc Diabetol | New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. | 2019 | Details |
| A11796 | 30737662 | Inflammation | Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis. | 2019 | Details |
| A12835 | 30261763 | Expert Rev Gastroenterol Hepatol | An update on the recent advances in antifibrotic therapy. | 2018 | Details |
| A14940 | 29164820 | Liver Int | Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. | 2017 | Details |
| A17704 | 27646933 | Gut | Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. | 2016 | Details |
| A31405 | 30633968 | Eur J Pharm Sci | Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. | 2019 | Details |
| A42394 | 34675485 | Drug Des Devel Ther | Saroglitazar - A Potential Therapeutic Option in Treating NASH? [Letter]. | 2021 | Details |
| A42499 | 34365663 | Hepatology | Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH. | 2021 | Details |
| A42561 | 34161617 | Hepatology | Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On! | 2021 | Details |
| A43326 | 31979903 | J Assoc Physicians India | Saroglitazar Improves Transaminases and Elastography in Patients with Diabetic Dyslipidemia and Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A50077 | 35535066 | J Clin Exp Hepatol | Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients. | 2021 | Details |
| A50112 | 35521658 | Antioxid Redox Signal | RGS7-ATF3-Tip60 Complex Promotes Hepatic Steatosis and Fibrosis by Directly Inducing TNFα. | 2022 | Details |
| A50622 | 35323681 | Metabolites | Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH. | 2022 | Details |
| A51306 | 35735253 | Hepatol Commun | Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. | 2022 | Details |